Eisai Wins Post-Operative Indication For Antiemetic Aloxi
This article was originally published in The Pink Sheet Daily
Executive Summary
Gained through the acquisition of MGI Pharma, drug adds indication for post-operative nausea and vomiting.
You may also be interested in...
Eisai’s Oral Aloxi Approved For Chemo-related Nausea/Vomiting
Antiemetic gained through MGI acquisition competes with oral therapies Zofran from GSK and Roche’s Kytril .
Eisai’s Oral Aloxi Approved For Chemo-related Nausea/Vomiting
Antiemetic gained through MGI acquisition competes with oral therapies Zofran from GSK and Roche’s Kytril .
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
MGI sale comes less than two weeks after the biopharma said it was exploring "strategic alternatives."